Skip to Content
Merck
CN

PZ0385

Sigma-Aldrich

PFE-360

≥98% (HPLC)

Synonym(s):

1-Methyl-4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-1H-pyrrole-2-carbonitrile, PF-06685360, PFE360

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C16H16N6O
CAS Number:
1527475-61-1
Molecular Weight:
308.34
UNSPSC Code:
12352202

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

room temp

SMILES string

CN1C(C#N)=CC(C2=CNC3=C2C(N4CCOCC4)=NC=N3)=C1

InChI key

IYQTYHISVSPMSU-UHFFFAOYSA-N

Biochem/physiol Actions

LRRK2 modulator
PFE-360 (PF-06685360) is a poten and elective inhibitor of LRRK2 kinase.

Pictograms

Flame
GHS02

Signal Word

Danger

Hazard Statements

H242

Hazard Classifications

Self-react. C

Storage Class Code

5.2 - Organic peroxides and self-reacting hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000036114

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Andrew B West
Experimental neurology, 298(Pt B), 236-245 (2017-08-03)
In the translation of discoveries from the laboratory to the clinic, the track record in developing disease-modifying therapies in neurodegenerative disease is poor. A carefully designed development pipeline built from discoveries in both pre-clinical models and patient populations is necessary
Kenneth Thirstrup et al.
Scientific reports, 7(1), 10300-10300 (2017-09-02)
Genetic variation in the leucine-rich repeat kinase 2 (LRRK2) gene is associated with risk of familial and sporadic Parkinson's disease (PD). To support clinical development of LRRK2 inhibitors as disease-modifying treatment in PD biomarkers for kinase activity, target engagement and
Michael Aagaard Andersen et al.
Toxicology, 395, 15-22 (2018-01-09)
Parkinson's disease (PD) is a progressive neurodegenerative disorder for which there is no existing therapeutic approach to delay or stop progression. Genetic, biochemical and pre-clinical studies have provided evidence that leucine-rich-repeat-kinase-2 (LRRK2) kinase is involved in the pathogenesis of PD

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service